Patents by Inventor Gabriel Lopez

Gabriel Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bioactive FUS1 peptides and nanoparticle-polypeptide complexes
    Publication number: 20060251726
    Abstract: A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product.
    Type: Application
    Filed: March 14, 2006
    Publication date: November 9, 2006
    Inventors: Jacki Lin, Ralph Arlinghaus, Tong Sun, Lin Ji, Bulent Ozpolat, Gabriel Lopez-Berestein, Jack Roth
  • Device containing cytophilic islands that adhere cells separated by cytophobic regions
    Publication number: 20060210595
    Abstract: The invention provides a device for adhering cells in a specific and predetermined position, and associated methods. The device includes a plate defining a surface and a plurality of cytophilic islands that adhere cells, isolated by cytophobic regions to which cells do not adhere, contiguous with the cytophilic islands. The islands or the regions or both may be formed of a self-assembled monolayer (SAM).
    Type: Application
    Filed: January 13, 2006
    Publication date: September 21, 2006
    Inventors: Rahul Singhvi, Amit Kumar, George Whitesides, Donald Ingber, Gabriel Lopez, Daniel Wang, Gregory Stephanopoulos
  • Electrokinetic molecular separtion in nanoscale fluidic channels
    Publication number: 20060169587
    Abstract: A method for separation of mixtures in fluidic systems through electrokinetic transport by use of nanochannels when the fluidic systems approach the size of an electrical double layer, thereby allowing separation based on charge. The disclosed apparatus comprises a T-chip with a nanochannel section. The method and apparatus are useful for separation of many molecular species, including peptides, proteins, and DNA.
    Type: Application
    Filed: October 4, 2004
    Publication date: August 3, 2006
    Inventors: Gabriel Lopez, Steve Brueck, Linnea Ista, Anthony Garcia, Dmiter Petsev, Paul Bisong, Michael O'Brien
  • Nanostructured devices for separation and analysis
    Publication number: 20060065528
    Abstract: Methods for forming an apparatus containing a nanofluidic device with a pattern having nanoscopic features includes producing a regular interference pattern in a substrate using two coherent light beams. In an embodiment, an apparatus includes a nanofluidic device having nanoscopic features in at least two dimensions. In an embodiment, a nanofludic device having nanoscopic features is formed using an ultraviolet source to generate a regular interference pattern.
    Type: Application
    Filed: February 3, 2005
    Publication date: March 30, 2006
    Inventors: Gabriel Lopez, Steven Brueck, Linnea Ista, Michael O'Brien
  • Fabrication of an anisotropic super hydrophobic/hydrophilic nanoporous membranes
    Publication number: 20060037477
    Abstract: Anisotropic hydrophobic/hydrophilic nanoporous membranes and methods of forming anisotropic hydrophobic/hydrophilic nanoporous membranes are disclosed. The method of forming the nanoporous membrane includes growing a nanoporous oxide film on a substrate. A nanoporous membrane having a top side and a bottom side can then be formed by partially separating the nanoporous oxide film from the substrate. A fluorocarbon film can be deposited on the top side of the nanoporous membrane by plasma polymerization. The disclosed anisotropic hydrophobic/hydrophilic nanoporous membranes can have extremely different hydrophobicity between the top side and the bottom side of the nanoporous membrane.
    Type: Application
    Filed: October 21, 2004
    Publication date: February 23, 2006
    Inventors: Gabriel Lopez, Plamen Atanassov, Dmitri Brevnov, Marcos Barela
  • Activation of aluminum for electrodeposition or electroless deposition
    Publication number: 20060032757
    Abstract: Method for treating an aluminum alloy surface for electrodeposition or electroless deposition of a metal or alloy on the surface, the surface is oxidized (e.g. anodized) to form aluminum oxide, and then the oxidized surface is chemically etched to render the surface amenable for electrodeposition or electroless deposition of the metal or alloy thereon. A metallic coating can be electrodeposited or electroless deposited on the treated surface.
    Type: Application
    Filed: August 11, 2005
    Publication date: February 16, 2006
    Inventors: Dmitri Brevnov, Tim Olson, Gabriel Lopez, Plamen Atanassov
  • Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
    Patent number: 6977244
    Abstract: The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: December 20, 2005
    Assignee: Board of Regents, The University of Texas Systems
    Inventors: Mar Tormo, Ana M. Tari, Gabriel Lopez-Berestein
  • Sorting charged particles
    Publication number: 20050061714
    Abstract: Charged particles may undergo two different separations within a single device, without manual intervention to effect the transfer of the particles between separations. In some embodiments, the device may be a Micro-Electro-Mechanical System.
    Type: Application
    Filed: September 18, 2003
    Publication date: March 24, 2005
    Inventors: Scott Sibbett, Gabriel Lopez
  • Stimuli responsive mesoporous materials for control of molecular transport
    Publication number: 20050013988
    Abstract: The present subject matter relates generally to design, synthesis, and characterization of materials with well-defined porous networks of molecular dimensions in which the size and surface energy of the pores can be externally and reversibly controlled to dynamically modulate the adsorption and transport of molecular species.
    Type: Application
    Filed: April 16, 2004
    Publication date: January 20, 2005
    Inventors: Qiang Fu, Venkata Goparaju, Linnea Ista, Yang Wu, Brett Andrzejewski, Yunfeng Lu, Larry Sklar, Timothy Ward, Gabriel Lopez
  • Compositions and methods related to lipid:emodin formulations
    Publication number: 20050008664
    Abstract: The present invention concerns the use of methods and compositions to provide an improved lipid:emodin formulation for the treatment of leukemias expressing bcr-abl and other cancer with elevated tyrosine kinase activity.
    Type: Application
    Filed: December 8, 2003
    Publication date: January 13, 2005
    Inventors: David Claxton, Robert Newman, Gabriel Lopez-Berestein
  • Stimuli-responsive hybrid materials containing molecular actuators and their applications
    Patent number: 6755621
    Abstract: The present invention provides a hybrid material and a method for forming a hybrid material comprising actuator made from a stimuli responsive polymer mounted in a porous framework. The present invention also provides devices employing the actuator of the present invention.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: June 29, 2004
    Assignee: Science & Technology Corporation @ University of New Mexico
    Inventors: Gabriel Lopez, Ashutosh Chilkoti, Plamen Atanassov, Venkata R. Goparaju
  • WT1 antisense oligos for the inhibition of breast cancer
    Publication number: 20040043950
    Abstract: The present invention provides methods for inhibiting the growth of breast cancer cells and methods for treating breast cancers expressing Wilms' Tumor 1 (WT1) gene product using a WT1 antisense oligonucleotide. It further provides methods of predicting breast cancer progression and methods for the screening of candidate substances for activity against breast cancer.
    Type: Application
    Filed: January 3, 2003
    Publication date: March 4, 2004
    Applicant: Board of Regents, The University of Texas System
    Inventors: Gabriel Lopez-Berestein, Ana Maria Tari, Pablo Zapata-Benavides
  • Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
    Publication number: 20040022772
    Abstract: Compositions comprising or encoding one or more peptides that inhibit the Bcr—Abl oncoprotein and that bind to molecules involved in Bcr—Abl function are disclosed. The peptides and polypeptides inhibit the growth of, and induce cell death of, Philadelphia chromosome-positive leukemia cells expressing the Bcr—Abl oncoprotein. Methods for treating leukemias (e.g., CML, ALL and AML), including autologous bone marrow transplant therapy, using the peptide and polypeptide compositions of the invention are also provided.
    Type: Application
    Filed: March 25, 2003
    Publication date: February 5, 2004
    Inventors: Ralph B. Arlinghaus, Jiaxin Liu, Gabriel Lopez-Berestein, Dai Lu, Yun Wu
  • Liposomal phosphodiester, phosphorothioate, and p-ethoxy oligonucleotides
    Publication number: 20040005353
    Abstract: An improved delivery system for antisense oligonucleotides involves a liposomal composition, comprising a liposome which consists essentially of neutral phospholipids and an antisense oligonucleotide that is entrapped in the liposome and is selected from the group consisting of phosphodiester oligonucleotides, phosphorothioate oligonucleotides, and p-ethoxy oligonucleotides.
    Type: Application
    Filed: June 16, 2003
    Publication date: January 8, 2004
    Inventors: Gabriel Lopez-Berestein, Ana Maria Tari
  • Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
    Publication number: 20030219474
    Abstract: The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.
    Type: Application
    Filed: March 12, 2003
    Publication date: November 27, 2003
    Inventors: Mar Tormo, Ana M. Tari, Gabriel Lopez-Berestein
  • Stimuli-responsive hybrid materials containing molecular actuators and their applications
    Patent number: 6615855
    Abstract: The present invention provides a hybrid material and a method for forming a hybrid material comprising actuator made from a stimuli responsive polymer mounted in a porous framework. The present invention also provides devices employing the actuator of the present invention.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: September 9, 2003
    Assignee: Science & Technology Corporation @t UNM
    Inventors: Gabriel Lopez, Ashutosh Chilkoti, Plamen Atanassov, Venkata Goparaju
  • Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1
    Publication number: 20030153526
    Abstract: The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.
    Type: Application
    Filed: December 20, 2002
    Publication date: August 14, 2003
    Inventors: Gabriel Lopez-Berestein, Ana M. Tari, Ralph B. Arlinghaus
  • Liposomal imexon
    Publication number: 20030129222
    Abstract: Disclosed are novel compositions comprising a lipid and imexon or a derivative thereof. Also disclosed are liposomal compositions comprising imexon or a derivative thereof. Methods for administrating pharmaceutically acceptable compositions comprising a lipid and imexon or a derivative thereof for the treatment of diseases, such as cancer, are also disclosed herein.
    Type: Application
    Filed: November 20, 2001
    Publication date: July 10, 2003
    Inventors: Gabriel Lopez-Berestein, William A. Remers, Evan Hersh
  • BCR-ABL directed compositions and uses for inhibiting Philadelphia chromesome stimulated cell growth
    Patent number: 6537804
    Abstract: The present invention provides methods for detecting and quantitating BCR-ABL gene products and other abnormal ABL gene products of Ph1-positive leukemic cells. The invention further provides methods for determining the relative number of leukemic cells compared with normal ABL cells to assess the tumor burden of a patient. In another aspect, the methods of the present invention can be used to determine a specific phase of leukemia, particularly chronic-phase CML.
    Type: Grant
    Filed: June 21, 1999
    Date of Patent: March 25, 2003
    Assignee: Board of Regents, The University of Texas Systems
    Inventors: Ralph B. Arlinghaus, Jiaxin Liu, Gabriel Lopez-Berestein, Dai Lu, Yun Wu
  • INHIBITION OF BCL-2 PROTEIN EXPRESSION BY LIPOSOMAL ANTISENSE OLIGODEOXYNUCLEOTIDES
    Publication number: 20030012812
    Abstract: The present invention provides novel compositions and methods for use in the treatment of Bcl-2-associated diseases like cancer, specifically, in the treatment of follicular lymphoma (FL). The compositions contain antisense oligonucleotides that hybridize to Bcl-2 nucleic acids, the gene products of which are known to interact with the tumorigenic protein Bcl-2. Used alone, or in conjunction with other antisense oligonucleotides, these compositions inhibit the proliferation of FL cancer cells.
    Type: Application
    Filed: October 4, 1996
    Publication date: January 16, 2003
    Inventors: MAR TORMO, ANA M. TARI, GABRIEL LOPEZ-BERESTEIN